SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-028942
Filing Date
2022-11-08
Accepted
2022-11-08 16:32:24
Documents
58
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20220930.htm   iXBRL 10-Q 1456264
2 EX-10.1 mrtx-2022930xex101.htm EX-10.1 64481
3 EX-31.1 mrtx-2022930xex311.htm EX-31.1 14090
4 EX-31.2 mrtx-2022930xex312.htm EX-31.2 14962
5 EX-32.1 mrtx-2022930xex321.htm EX-32.1 7748
  Complete submission text file 0001628280-22-028942.txt   5751451

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20220930.xsd EX-101.SCH 36279
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20220930_cal.xml EX-101.CAL 54549
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20220930_def.xml EX-101.DEF 151594
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20220930_lab.xml EX-101.LAB 448985
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20220930_pre.xml EX-101.PRE 275351
52 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20220930_htm.xml XML 930559
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 221369416
SIC: 2834 Pharmaceutical Preparations